IDEXX Laboratories, Inc. vs Global X NASDAQ 100 Covered Call ETF — how do they compare? IDEXX Laboratories, Inc. trades at $560 (market cap $44.48B), while Global X NASDAQ 100 Covered Call ETF trades at $17.78. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | QYLD | |
|---|---|---|
Market Cap | $44.48B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $766.68 | $18.52 |
52-Week Low | $520.87 | $16.46 |
Enterprise Value | $45.38B | — |
Signals from Pluang's Aura AI — not financial advice
IDXX trades at $563.79, down 0.64% today but maintains strong fundamental momentum with consistent earnings beats and robust profitability. The stock shows bullish technical signals with support at $563 and resistance at $572, while valuation metrics remain elevated. Recent Q1 2026 results exceeded expectations with EPS of $3.47 versus $3.41 estimates, supporting the company's leadership in veterinary diagnostics.
Outlook remains positive given strong analyst support (59% buy ratings) and innovation pipeline, though premium valuations and competitive pressures present risks. Revenue growth trajectory and expanding margins provide fundamental support for continued upside potential in the pet healthcare sector.
QYLD trades at $17.66, down 0.84% with a bearish technical signal from moving averages. The ETF's covered-call strategy generates high income but has underperformed the Nasdaq-100's growth over the long term. Recent dividend payments of $0.18-$0.19 per share continue the fund's income-focused approach while technical indicators show neutral oscillators but bearish momentum signals.
The outlook remains challenging as QYLD's high yield comes at the cost of capital appreciation. While attractive for income-seeking investors, the fund faces structural headwinds in strong bull markets. Key risks include NAV erosion during market rallies and competition from lower-fee alternatives like GPIQ.
Trailing returns across standard periods
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →